Convalescent Plasma Treatment Enters 2nd Phase Trial

Translator:

Editor:

Laila Afifa

  • Font:
  • Ukuran Font: - +
  • TEMPO.CO, Jakarta - The convalescent plasma treatment for coronavirus patients in Indonesia will enter its second phase of the clinical trial. The first phase was completed at the Gatot Subroto Army Hospital (RSPAD) in Jakarta. 

    Results from the first trial show that plasma treatment is safe and does not present any side effects for those who are treated. 

    "It is safe, has not produced any side effects, and can be concluded that [this type of treatment] can be given to patients with mild symptoms," the Research and Technology Minister Bambang Brodjonegoro said in Tuesday’s virtual press conference on vaccine development, therapy, and its innovations. 

    He explained that the second clinical trial will involve a larger number of patients in 29 hospitals. It coincides with the development of a measuring tool for specific antibody levels by the Eijkman Institute for Molecular Biology. 

    Apart from the convalescent plasma treatment, Minister Bambang revealed that the development of the GeNose device by the team of researchers from Yogyakarta’s Gadjah Mada University (UGM) has entered its second phase. 

    Read: Solo City in Need of Convalescent Plasma Donors

    Zacharias Wuragil